Vaxcyte (PCVX)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Vaxcyte (PCVX)
Vaxcyte Inc is a vaccine company seeking to improve global health by developing novel vaccines to treat patients suffering from the most common and deadly diseases. Its product comprises. of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-24, VAX-A1, and VAX-PG.
Key Insights
Critical company metrics and information
Share Price
$93.31Market Cap
$11.63 BillionTotal Outstanding Shares
124.64 Million SharesTotal Employees
254Dividend
No dividendIPO Date
June 12, 2020SIC Description
Biological Products, (no Disgnostic Substances)Homepage
https://www.vaxcyte.com
Historical Stock Splits
Execution Date | Split Amount |
---|---|
No Historical Stock Splits |
Cash Flow Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Net Cash Flow From Investing Activities, Continuing | $-1.46 Billion |
Net Cash Flow | $505.27 Million |
Exchange Gains/Losses | $-8.61 Million |
Net Cash Flow From Operating Activities | $-470.04 Million |
Net Cash Flow From Financing Activities, Continuing | $2.45 Billion |
Net Cash Flow From Investing Activities | $-1.46 Billion |
Net Cash Flow From Financing Activities | $2.45 Billion |
Net Cash Flow, Continuing | $513.88 Million |
Net Cash Flow From Operating Activities, Continuing | $-470.04 Million |
Income Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Diluted Earnings Per Share | $4.60 |
Operating Income/Loss | $-604.05 Million |
Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
Basic Earnings Per Share | $4.60 |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
Basic Average Shares | $119.39 Million |
Net Income/Loss Attributable To Parent | $-507.65 Million |
Net Income/Loss Available To Common Stockholders, Basic | $-507.65 Million |
Other Operating Expenses | $151.77 Million |
Preferred Stock Dividends And Other Adjustments | $0.00 |
Income/Loss From Continuing Operations Before Tax | $-507.65 Million |
Net Income/Loss | $-507.65 Million |
Research and Development | $447.18 Million |
Revenues | $0.00 |
Operating Expenses | $604.05 Million |
Depreciation and Amortization | $5.00 Million |
Income/Loss From Continuing Operations After Tax | $-507.65 Million |
Diluted Average Shares | $119.39 Million |
Balance Sheet
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Current Liabilities | $123.79 Million |
Noncurrent Liabilities | $18.32 Million |
Wages | $12.24 Million |
Prepaid Expenses | $10.59 Million |
Other Current Assets | $2.20 Billion |
Fixed Assets | $163.24 Million |
Equity Attributable To Noncontrolling Interest | $0.00 |
Liabilities | $142.11 Million |
Noncurrent Assets | $1.35 Billion |
Non-current Prepaid Expenses | $284000.00 |
Other Current Liabilities | $93.33 Million |
Equity Attributable To Parent | $3.42 Billion |
Accounts Payable | $18.22 Million |
Equity | $3.42 Billion |
Current Assets | $2.21 Billion |
Assets | $3.56 Billion |
Liabilities And Equity | $3.56 Billion |
Other Non-current Assets | $1.18 Billion |
Historical Dividends
Announcement Date | Payment Date | Record Date | Amount | Frequency |
---|---|---|---|---|
No historical dividends |
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ 2024 Financhle. All Rights Reserved.